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ABSTRACT

A small-molecule Stat3 dimerization inhibitor, S3I-M2001,
is described and the dynamics of intracellular processing of
activated Stat3 within the context of the biochemical and
biological effects of the Stat3 chemical probe inhibitor are
elucidated. S3I-M2001 is a newly-identified oxazole-based
peptidomimetic of the Stat3 Src Homology (SH) 2 domainbinding phosphotyrosine peptide that selectively disrupts
active Stat3:Stat3 dimers. Stat3-dependent malignant transformation, survival, and migration and invasion of mouse and
human cancer cells harboring persistently-activated Stat3
were inhibited by S3I-M2001. S3I-M2001 inhibited Stat3dependent transcriptional regulation of tumor survival genes,
such as Bcl-xL. The disclosed compound is useful as a new
potential treatment for certain cancers.
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STAT3 INHIBITOR HAVING ANTI-CANCER
ACTIVITY AND METHODS

cessing of Stat3 to understand Stat3's role as a signaling
intermediate and a molecular mediator of the events leading
to carcinogenesis and malignant progression.
The computational analysis of the interaction between the
Stat3 SH2 domain-binding pTyr peptide sequence and the
SH2 domain, per the X-ray crystal structure of Stat3b bound
to DNA (14), can generate valuable information about key
structural requirements for the Stat3:Stat3 dimer formation
that will facilitate the design of effective small-molecules to
disrupt the dimer. Such molecules can be used for therapeutic
purposes and as tools for investigating the regulation of Stat3
protein. In the molecular modeling of the Stat3 pTyr-SH2
domain interaction, the peptidomimetic inhibitor, ISS 610
(10) derived from the Stat3 SH2 domain-binding pTyr (Y*)
peptide, PY*LKTK (9), was used as a chemical probe for
interrogating the Stat3:Stat3 dimer interface in order to derive
non-peptide mimics.
Herein, we describe the design and characterization of a
novel oxazole-based peptidomimetic, designated S3IM2001, as a selective disruptor of Stat3:Stat3 dimerization
and inhibitorofStat3 activation. We also describe our study of
the stability and intracellular processing of aberrant Stat3
within the context of the activity of S3I-M2001 as a Stat3
inhibitor.

CROSS-REFERENCE TO RELATED
APPLICATIONS
The present application is a national phase application of
International Application No. PCT/US2007/086453 filed on
Dec. 5, 2007, which claims priority to U.S. Provisional Patent
Application No. 60/868,794 filed on Dec. 6, 2006, each of
which is incorporated by reference herein it its entirety.
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STATEMENT OF GOVERNMENT INTEREST
This invention was made with support from the U.S. Government under Grant CA 106439 awarded to James Turkson
by the National Cancer Institute. Accordingly, the government has certain rights in the invention.
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FIELD OF THE INVENTION

20

The present invention relates to the field of cellular biology
and, more particularly, to a novel inhibitor effective against at
least one protein of a certain family of proteins of importance
in cancer cell physiology and known as Signal Transducers
and Activators of Transcription (STAT).

25

SUMMARY OF THE INVENTION

BACKGROUND OF THE INVENTION
STAT proteins were originally discovered as latent cytoplasmic transcription factors that mediate cytokine and
growth factor responses (1, 2). Seven members of the family,
Stat!. Stat2. Stat3. Stat4. Stat5a and Stat5b, and Stat6, mediate several physiological effects including growth and differentiation, survival, development and inflammation. STATs
are SH2 domain-containing proteins. Upon ligand binding to
cytokine or growth factor receptors. STATs become phosphorylated on critical Tyr residue (Tyr705 for Stat3) by growth
factor receptors, cytoplasmic Janus kinases (Jaks) or Src family kinases. Two phosphorylated and activated STAT monomers dimerize through reciprocal pTyr-SH2 domain interactions, translocate to the nucleus, and bind to specific DNAresponse elements of target genes, thereby inducing gene
transcription (1, 2). In contrast to normal STAT signaling,
many human solid and hematological tumors harbor aberrant
Stat3 activity (3-8 for reviews).
Constitutive Stat3 activity mediates dysregulated growth
and survival, angiogenesis, as well as suppresses the host's
immune surveillance of the tumor, making constitutivelyactive Stat3 a critical molecular mediator of carcinogenesis
and tumor progression.
Genetic and other molecular evidence reveals persistent
Tyr phosphorylation of Stat3 is mediated by aberrant
upstream Tyr kinases and shows cancer cell requirement for
constitutively-active and dimerized Stat3 for tumor maintenance and progression. Thus, in numerous proof-of-concept
studies (9-13 ), inhibition of Stat3 activation or disruption of
dimerization induces cancer cell death and tumor regression.
How aberrant Stat3 is regulated for meeting the tumor-specific requirements in malignant cells remains undefined.
There have been no studies into defining the molecular details
of how malignant cells regulate aberrant Stat3 and how this
regulation changes upon Stat3 inhibition prior to the onset of
phenotypic changes, although knowing these events will
facilitate efforts in modulating aberrant Stat3 for managing
human cancers. Small-molecule Stat3 inhibitors thus provide
tools for probing the molecular dynamics of the cellular pro-
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Signal Transducer and Activator of Transcription (Stat) 3 is
hyperactivated in many human tumors and represents a valid
target for small-molecule anticancer drug design. We present
a novel small-molecule Stat3 dimerization inhibitor, S3IM2001 and describe the dynamics of intracellular processing
of activated Stat3 within the context of the biochemical and
biological effects of the Stat3 chemical probe inhibitor. S3IM2001 is a newly-identified oxazole-based peptidomimetic
of the Stat3 Src Homology (SH) 2 domain-binding phosphotyrosine peptide that selectively disrupts active Stat3:Stat3
dimers. Consequently, hyperactivated Stat3, which hitherto
occurs as "dot-like" structures of nuclear bodies, undergoes
an early aggregation into non-functional perinuclear aggresomes and a late-phase proteasome-mediated degradation in
malignant cells treated with S3I-M2001. Thus, S3I-M2001
inhibited Stat3-dependent transcriptional regulation of tumor
survival genes, such as Bcl-xL. Furthermore. Stat3-dependent malignant transformation, survival, and migration and
invasion of mouse and human cancer cells harboring persistently-activated Stat3 were inhibited by S3I-M2001. The
ectopic expression of Stat3 SH2 domain rescued cells from
S3I-M2001-induced apoptotic effects, further confirming a
dimerization inhibition mechanism. Finally, S3I-M2001
inhibited growth of human breast tumor xenografts. The
study identifies a novel Stat3 inhibitor, S3I-M2001 and provides evidence for antitumor cell effects mediated in part
through a biphasic loss of functional Stat3. The disclosed
study represents the first on intracellular Stat3 stability and
processing following inhibition by a small-molecule that has
significant antitumor activity.
With the foregoing in mind, the present invention advantageously provides a compound designated as S3I-M2001
and having a chemical structure according that shown in FIG.
lB, or a pharmaceutically acceptable salt thereof. The invention further includes a pharmaceutically acceptable composition containing the compound shown in FIG. lB. In one
preferred embodiment of the invention, a pharmaceutically
acceptable composition contains the compound S3I-M2001
in an effective amount for inhibiting Stat3 dimerization upon
contacting a mammalian cell.
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Method aspects of the invention include treating a mammalian cell having a dysfunctional Stat3 protein, the method
comprising contacting the cell with the compound S3IM2001 or with a composition containing the compound.
Treatment also includes inhibiting a mammalian cell harboring constitutively active Stat3 by contacting the cell with an
effective amount of the compound S3I-M2001 or a composition containing the compound so as to inhibit the Stat3 activity in the cell. For example, in a method of treating human
breast or pancreatic cancer characterized by a constitutively
active level of Stat3, the method comprises administering a
sufficient amount of the compound S3I-M2001, or a composition containing it, to contact cancer cells in the patient's
breast or pancreas.
Alternatively, a patient may be treated to inhibit growth of
a human breast cancer tumor by administering to the patient
a sufficient amount of the compound of S3I-M2001 or a
composition containing S3I-M2001. More broadly viewed,
the invention includes a method of inhibiting migration of a
malignant cell, the method comprising contacting the cell
with S3I-M2001 as the compound or in a pharmaceutically
acceptable composition.

pared from NIH3T3 fibroblasts transiently co-transfected
with the Stat3-dependent (pLucTKS3) or the Stat3-independent (pLucSRE) luciferase reporter together with the v-Src
plasmid with and without Stat3b plasmid and treated with or
without S3I-M2001; (B) shows EMSA analysis of STATs
DNA-binding activities in independently-prepared cell
lysates of activated Stat! or Stat3, or mixed pool oflysates of
both proteins and pre-treated with or without S3I-M2001
concentrations for 30 min at room temperature prior to incubation with radiolabeled hSIE oligonucleotide probe, as
described in "Methods"; (C) depicts in vitro ELISA for the
binding ofLck-SH2-GST to the conjugate biotinylated pTyrpeptide (EPQpYEEIEL) and effects ofS3I-M2001; and (D)
Immunofluorescence imaging/confocal microscopy of Stat3
nuclear localization in NIH3T3/hEGFR treated with or without 100 mM S3I-M2001 for 3 h prior to stimulation or
unstimulation by EGF (rhEGF) for 10 min.: positions of
STAT:DNA complex in gel are labeled; values are the mean
and S.D. of 6 replicate experiments; data are representative of
three independent studies;
FIG. 4 shows fluorescence with confocal microscopy of
intracellular Stat3 signal; fluorescence microscopy of the
NIH3T3/v-Src fibroblasts stably expressing the plasmids for
(A) and (B) yellow fluorescent protein (YFP)-tagged Stat3
(NIH3T3/v-Src/Stat3-YFP) or (C) green fluorescent protein
(GFP) (NIH3T3/v-Src/GFP) and treated with or without S3IM2001 for the indicated times in the presence or absence of
the proteasome inhibitor, MG132 (1-h pre-treatment); and
Laser scanning confocal microscopy of (D) NIH3T3/v-Src/
GFP (left panel) or NIH3T3/v-Src/Stat3-YFP (right panel) or
(E) NIH3T3/v-Src/Stat3-YFP and treated with or without
S3I-M2001 or Cisplatin for the indicated times; fluorescence
and confocal images were collected using Nikon Eclipse
TE200 and Leica TCS SP5 microscopes, respectively;
Arrows denote fluorescence or cells previously showing fluorescence, or aggregated Stat3-YFP; data are representative of
2-3 independent studies:
FIG. 5 displays immunoblotting analyses of intracellular
Stat3 signal; SDS-PAGE/Westem blot analysis of(A) wholecell lysates from NIH3T3/v-Src/Stat3-YFP probing forYFP,
Stat3 or b-actin; and (B) of Stat3 immunoprecipitates from
NIH3T3/v-Src fibroblasts blotting for Ubiquitin, or NIH3T3/
v-Src whole-cell lysates blotting for Stat3 or b-actin; data are
representative of 2-3 independent studies;
FIG. 6 shows immunofluorescence with laser scanning
confocal imagining of Stat3 aggregation into perinuclear
aggresomes induced by S3I-M2001: immunofluorescence
and confocal microscopy ofNIH3T3/v-Src fibroblasts growing in culture treated with or without S3I-M2001 or Cisplatin
for the indicated times, (A) fixed and stained with rabbit
anti-Stat3 antibody (green) or DAPI nuclear staining (blue);
(B) allowed to recover from the effects ofS3I-M2001 for 2 h
or 19 h prior to fixing and staining for Stat3 or with DAPI; or
(C) fixed and stained with rabbit antibody against Stat3
(green) or goat antibody against Hook2 (blue); arrows denote
aggregated Stat3 and localization of Hook2 protein; images
were captured using Leica TCS SP5 laser scanning confocal
microscope and are representative of 3 independent experiments;
FIG. 7 shows effect ofS3I-M2001 on cell viability, malignant transformation, apoptosis and Bcl-xL expression: in (A)
IC50 values for the S3I-M2001-induced loss of cell viability
determined by WST-1 assay; (B) anchorage-independent
growth in soft-agar suspension of malignant cells (NIH3T3/
v-Src. Pane-I and NIH3T3/v-Ras) treated with or without
S3I-M2001 every three days; (C) TUNEL staining for DNA
damage in normal NIH3 T3 and NIH3 T3/v-Src, human endot-
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Some of the features, advantages, and benefits of the
present invention having been stated, others will become
apparent as the description proceeds when taken in conjunction with the accompanying drawings, presented for solely
for exemplary purposes and not with intent to limit the invention thereto, and in which:
FIG. 1 shows computational modeling of S3I-M2001
bound to the Stat3 SH2 domain and S3I-M2001 chemical
structure according to an embodiment of the present invention; in panel (A) S3I-M2001 (green) is shown docked to the
SH2 domain of Stat3, along with Stat3 peptidomimetic
inhibitor, ISS 610 (yellow) (10); and the chemical structures
of S3I-M2001 (panel B) or ISS 610 (panel C) are shown;
FIG. 2 depicts the effects ofS3I-M2001 on STATs activation, and on pJakl, pSrc, pErkl/2; (A) shows EMSA analysis
ofSTATs DNA-binding activities in nuclear extracts containing activated Stat3 (left panel) or Stat! and Stat3 (middle
panel) and pre-treated with S3I-M2001 concentrations for 30
min. at room temperature prior to incubation with radiolabeled hSIE oligonucleotide probe, and IC50 values for the
inhibition of STATs DNA-binding activity in vitro (right
panel) derived, as described in "Methods"; (B) EMSA analysis of Stat3 DNA-binding activity in nuclear extracts from
NIH3T3/v-Src or MDA-MB-231 cells, or from recombinant
human EGF (rhEGF)-stimulated NIH3T3/hEGFR mouse
fibroblasts treated with or without S3I-M2001; and (C) SDSPAGE/Westem blot analysis of whole-cell lysates prepared
from S3I-M2001-treated or untreated NIH3T3/v-Src or
MDA-MB-435 cells probing for pTyr705Stat3, Stat3, pJak,
Jakl, pSrc, Src, pErkl/2, Erkl/2, and b-actin; positions of
STAT:DNA complex in gel, pTyrStat3 and Stat3 are labeled;
values are the mean and S.D. of3 replicate experiments: data
are representative of three independent studies; IC50 values
were determined by quantifying by ImageQuant the bands
corresponding to the STAT:DNA complexes; control lanes
represent nuclear extracts untreated with S3I-M2001 or
nuclear extract preparations from cells untreated with the
compound;
FIG. 3 illustrates the effects of S3I-M2001 on Stat3 transcriptional activity and dimerization, and nuclear localization, and on the Lck-SH2 domain function; in (A) are shown
luciferase reporter measurements in cytosolic extracts pre-
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helial (HUVEC), breast cancer cells (MDA-MB-453, MDAMB-231 and MDA-MB-435), and the normal breast epithelial MCF-lOA cells treated with or without S3I-M2001 for48
h; Stat3 activity status is indicated as (+), pStat3 (activated),
(-), no Stat3 activity; (D) Annexin V binding and Flow
Cytometry of NIH3T3/v-Src fibroblasts transfected with
empty vector, pcDNA3 (3T3/v-Src/pcDNA3) or the Stat3
SH2 domain (3T3/v-Src/ST3-SH2) for 4 h or untransfected
(3T3/v-Src) and treated with or without 100 mM S3I-M2001
for additional 24 h; and (E) SDS-PAGE and Western blot
analysis for Bcl-xL in NIH3T3/v-Src and MDA-MB-435
cells; images shown are representative of 2-3 independent
studies; values are the mean and S.D. of3-4 replicate experiments;
FIG. 8 shows that S3I-M2001 suppresses malignant cell
migration and invasion and inhibits growth of human breast
tumor xenografts; in (A) viral Src-transformed mouse fibroblasts (NIH3T3/v-Src), human breast cancer (MDA-MB231) and pancreatic cancer (Pane- I) cells were seeded for
studies in migration on filters or invasion on matrigel-coated
filters in Bio-Coat chambers and treated with or without S3IM2001 (100 mM) for 24; cells on other side of filters were
photographed (upper panel) and quantified under light microscope (lower panel; percent inhibition in parenthesis): human
breast (MDA-MB-231) tumor-bearing mice were given S3IM2001 (5, 10 and 20 mg kg-1) i.v. every 2 or 3 days; (B)
Tumor sizes, measured every 2 or 3 days, were converted to
tumor volumes and plotted against treatment days; (C) EMSA
analysis ofStat3 DNA-binding activity in lysates from tumor
tissues extracted from one control and two residual treated
tumors (Tl and T2) 3 days after the last S3I-M2001 (5 mg
kg-1) injection; and (D) SDS-PAGE/Western blot analysis of
whole-cell lysates from control or residual treated (T2) tumor
tissue and probing for pTyr705Stat3 and Stat3; values are the
mean and S.D. of three independent experiments each in
duplicates or replicates of 12 tumor-bearing mice in each
group; data are representative of 2-3 independent experiments; bands ofStat3:DNA complexes, pStat3 and Stat3 are
shown:
FIG. 9 shows effects ofS3I-M2001 on STATs activation by
EMSA analysis of Stat3 DNA-binding activity in cell lysate
containing activated Stat3 prepared from Sf-9 cells infected
with Stat3. Jakl, and c-Src baculoviruses: positions of STAT:
DNA complex in gel are labeled; data shown are representative of 3 independent experiments:
FIG. 10 depicts the effects of S3I-M2001 on Stat3 phosphorylation by immunohistochemical stmmng for
pTyr705Stat3 in NIH3T3/v-Src or MDA-MB-435 cells;
images are representative of three independent studies;
FIG. 11 illustrates the effect of S3I-M2001 on malignant
transformation; images of cellular morphology are visualized
using light microscope of normal NIH3T3 mouse fibroblasts
and v-Src-transformed counterparts (NIH3T3/v-Src) growing in culture and treated with or without different concentrations ofS3I-M2001for48 h; the images shown are representative of 2 independent studies; and
FIG. 12 shows the effect of S3I-M2001 on Bcl-xL expression by immunohistochemical staining for Bcl-xL in
NIH3T3/v-Src and human breast cancer MDA-MB-435
cells; intense red staining indicates presence ofBcl-xL, while
blue staining indicates absence ofBcl-xL; the images shown
are representative of3 independent studies.

which preferred embodiments of the invention are shown.
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or
testing of the present invention, suitable methods and materials are described below. Any publications, patent applications, patents, or other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the
present specification, including any definitions, will control.
In addition, the materials, methods and examples given are
illustrative in nature only and not intended to be limiting.
Accordingly, this invention may, however, be embodied in
many different forms and should not be construed as limited
to the illustrated embodiments set forth herein. Rather, these
illustrated embodiments are provided so that this disclosure
will be thorough and complete, and will fully convey the
scope of the invention to those skilled in the art. Other features and advantages of the invention will be apparent from
the following detailed description, and from the claims.
Abbreviations used herein are as generally accepted and
used by those skilled in the art and include the following:
STAT, signal transducer and activator of transcription; PBS,
phosphate-buffered saline; EMSA, electrophoretic mobility
shift assay; FBS, fetal bovine serum; PMSF, phenylmethylsulfonylfluoride; and PNPP, p-nitrophenyl phosphate; YFP,
yellow fluorescent protein; GFP, green fluorescent protein;
CVFF, consistent valence forcefield; and CCDC, Cambridge
Crystallographic Data Center.
Those skilled in the art will recognize that this invention
encompasses pharmaceutical compositions and dosage forms
containing the disclosed compound of the invention as an
active ingredient. A "pharmaceutically acceptable composition" is compatible with the subject's physiology and may
contain one or more pharmaceutically acceptable carriers or
excipients. Some of these pharmaceutical compositions may
be single unit dosage forms suitable for oral, topical, mucosa!
(e.g., nasal, pulmonary, sub lingual, vaginal, buccal, or rectal),
parenteral (e.g., subcutaneous, intravenous, bolus injection,
intramuscular, or intraarterial ), or trans dermal administration
to a patient. As known to the skilled, examples of dosage
forms include, without limitation: tablets; caplets; capsules,
such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; ointments; poultices;
pastes; powders; dressings; creams; plasters; solutions;
patches; aerosols such as nasal sprays or inhalers; gels; liquid
dosage forms for oral or mucosa! administration, including
aqueous or non-aqueous liquid suspensions, oil-in-water
emulsions, or water-in-oil liquid emulsions, solutions, and
elixirs; liquid dosage forms suitable for parenteral administration to a patient; and sterile solids such as crystalline or
amorphous solids that can be reconstituted to provide liquid
dosage forms suitable for parenteral administration to a
patient.
The skilled will also know that a formulation should suit
the mode of administration. For example, oral administration
may require an enteric coating to help protect the active
ingredient from degradation in the gastrointestinal tract. The
S3I-M2001 may also be administered in a liposomal formulation to shield it from enzymes that may degrade it, to facilitate transport in the blood and to aid in its delivery across cell
membranes.
The composition of S3I-M2001, shape, and type of dosage
forms of the invention will typically vary depending on the
intended use. Thus, it would follow that in the acute treatment
of a disease the dosage may contain larger amounts of the
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The present invention will now be described more fully
hereinafter with reference to the accompanying drawings, in
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compound, whereas in the chronic treatment of the same
disease a lower dosage may suffice. Likewise, smaller
amounts ofS3I-M2001 may be used in a parenteral dose than
in an dose form used to treat the same disease. The ways in
which specific dosage forms for the invention may be
changed will be appreciated by the skilled, particularly with
reference to a recognized treatise such as Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton Pa.
(1990).
As used herein, the term "Stat" refers to signal transducers
and activators of transcription, which represent a family of
proteins that, when activated by protein tyrosine kinases in
the cytoplasm of the cell, migrate to the nucleus and activate
gene transcription. Examples of mammalian STATs include
STAT 1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and
STATE.
The term "pharmaceutically acceptable salt or prodrug" is
intended to describe any form (such as an ester, phosphate
ester, salt of an ester or a related group) of a compound of the
invention, which, upon administration to a subject, provides
the mature or base compound (e.g., the Stat3-inhibitory compound S3I-M2001). Pharmaceutically compatible salts
include those derived from inorganic or organic bases and
acids which are compatible with the subject's physiology.
Suitable salts include those derived from alkali metals such as
potassium and sodium, alkaline earth metals such as calcium
and magnesium, among numerous other acids well known in
the pharmaceutical art. Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example
hydrolyzed or oxidized, in the host to form the compound of
the present invention. Typical examples of prodrugs include
compounds that have biologically labile protecting groups on
a functional moiety of the active compound. Prodrugs include
compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound.
The terms "signaling" and "signaling transduction" represent the biochemical process involving transmission of extracellular stimuli, via cell surface receptors through a specific
and sequential series of molecules, to genes in the nucleus
resulting in specific cellular responses to the stimuli.
"Constitutive activation" and "constitutively active," as in
the constitutive activation of the STAT pathway, refers to a
condition where there is an abnormally elevated level of
tyrosine phosphorylated STAT3 within a given cell(s). e.g.,
cancer cells, as compared to a corresponding normal (e.g.,
non-cancer or non-transformed) cell. Constitutive activation
of STAT3 has been exhibited in a large variety of malignancies, including, for example, breast carcinoma cell lines; primary breast tumor specimens; ovarian cancer cell lines and
tumors: multiple myeloma tumor specimens; and blood
malignancies, such as acute myelogenous leukemia, as
described in published PCT international application WO
00/44774 (Jove. R. et al.), the disclosure of which is incorporated herein by reference in its entirety.
Methods for determining whether a human or non-human
mammalian cell or subject has abnormally high levels of
constitutively-activated Stat3 are known in the art and are
described, for example, in U.S. patent publication 20040138189-Al and PCT publication 02/078617 A, each of
which are incorporated herein by reference in its entirety.
Optionally, the methods of the invention further comprise
identifying a patient suffering from a condition (e.g., cancer)
associated with an abnormally elevated level of tyrosine
phosphorylated STAT3, or determining whether the cancer

cells can be characterized as having abnormally elevated
levels of tyrosine phosphorylated Stat3.
As used herein, the terms "treat," "treating" or "treatment"
refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow
down (lessen) an undesired physiological change or disorder,
such as the development or spread of cancer or other proliferation disorder. For purposes of this invention, beneficial or
desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of
disease progression, amelioration or palliation of the disease
state, and remission (whether partial or total), whether detectable or undetectable. For example, treatment with a compound of the invention may include reduction of undesirable
cell proliferation, and/or induction of apoptosis and cytotoxicity. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in
need of treatment include those already with the condition or
disorder as well as those prone to have the condition or
disorder or those in which the condition or disorder is to be
prevented or onset delayed. Optionally, the patient may be
identified (e.g., diagnosed) as one suffering from the disease
or condition (e.g. proliferation disorder) prior to administration of the Stat3 inhibitor of the invention.
As used herein, the term "(therapeutically) effective
amount" refers to an amount of the compound of the invention
or a composition containing the compound effective to treat a
disease or disorder in a mammal or a mammalian cell. In the
case of cancer or other proliferation disorder, the therapeutically effective amount of the agent may reduce (i.e., slow to
some extent and preferably stop) unwanted cellular proliferation; reduce the number of cancer cells; reduce the tumor size;
inhibit (i.e., slow to some extent and preferably stop) cancer
cell infiltration into peripheral organs; inhibit (i.e., slow to
some extent and preferably stop) tumor metastasis; inhibit, to
some extent, tumor growth; reduce Stat3 signaling in the
target cells (such as by inhibiting the binding of DNA and
Stat3), and/or relieve, to some extent, one or more of the
symptoms associated with the cancer. To the extent the
administered compound or composition prevents growth and/
or kills existing cancer cells, it may be cytostatic and/or
cytotoxic. For cancer therapy, efficacy can, for example, be
measured by assessing the time to disease progression (TTP)
and/or determining the response rate (RR).
The terms "inhibit" or "inhibitory amount" when referring
to the compound of the invention indicate an amount which
slows or stops growth or proliferation of a target cell, such as
a tumor cell, either in vitro or in vivo, irrespective of the
mechanism by which cell growth is inhibited (e.g., by cytostatic properties, cytotoxic properties, etc.).
The terms "cell" and "cells" are used interchangeably
herein and are intended to include either a single cell or a
plurality of cells, in vitro or in vivo, unless otherwise specified.
FIGS. 1-8 visually present various aspects of the presently
described invention and are more fully discussed below with
reference to the results and conclusions derived from the
investigation leading to the invention.
Methods
Cells and Reagents.
Normal mouse fibroblasts (NIH3T3) and counterparts
transformed by v-Src transformed (NIH3T3/v-Src), v-Ras
(NIH3T3/v-Ras), or overexpressing the human EGFR
(NIH3T3/hEGFR), human breast cancer (MDA-MB-435,
MDA-MB-453, MDA-MB-231 andMDA-MB-468), immortalized human breast epithelial cells. MCF-1 OA, and pancre-
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atic cancer (Pane- I) cell lines have all been previously
described (9-I2, I7, IS, 40). Human umbilical vein cells
(HUVEC) was a kind gift Dr. S. Chellappan of Moffitt Cancer
Center and Research Institute (Tampa, Fla.). Cells were
grown in Dulbecco's modified Eagle's medium (DMEM)
containing 5% iron-supplemented bovine calf serum: MCFIOA were grown in DMEM:FI2 media supplemented with
5% FBS, I 0 mg mL- I insulin, 500 ng mL- I hydrocortisone,
20 ng mL-I EGF, and IOO ng mL-I cholera toxin. HUVEC
cells were grown in Ham's FI2k medium with 2 mM
L-glutamine containing 1.5 g L-I sodium bicarbonate and
supplemented with O.I mg mL-I heparin and 0.03 mg mL-I
endothelial cell growth supplement, and IO% FBS. WST-I
viability assay reagent was obtained from Roche and TUNEL
assay kit was from BD Biosciences Pharmingen. Each treatment condition is a single dose at the indicated concentration
or O.I% DMSO (vehicle) as control. Anti-Hook2 antibody
was from Santa Cruz. Plasmids. The pLucTKS3 and pLucSRE luciferase reporters have been previously reported (I 7,
I9).
Computational Modeling of the Stat3 SH2 Domain-ISS 6IO
Complex.
As a first step towards designing new Stat3 inhibitors as
probes or novel anticancer therapeutics, molecular modeling
of the Stat3 SH2 domain was performed. The Stat3 SH2
domain contains trigonal arrangement of shallow pockets,
deemed accessible by suitably-substituted heterocyclic scaffolds, such as the oxazole, S3I-M2001. Docking of S3IM2001 into Stat3 was performed using the GOLD software
(I5) by CCDC. Compounds were drawn with Insight II (Accelrys), and energy minimized to a local minimum using the
CVFF forcefield. The Stat3 protein was prepared for use in
GOLD by adding Hydrogen atoms to the X-ray crystal structure, lBGl.pdb (I4. Compounds were docked by GOLD IO
times each using default settings within GOLD and were
scored using the default GO LDScore scoring function. Maximum ligand flexibility was allowed during docking cycles by
allowing ring flipping, amide cis/trans alteration, and amine
flipping. After I 0 <lockings, the conformation with the highest
score for each compound was considered and analyzed.
Compound Synthesis.
The design strategy for the construction of the oxazole
scaffold was carried out using standard synthetic procedures,
following the principle of rapid incorporation of structural
diversity into an acyclic precursor, with subsequent late stage
aromatization providing the desired heteroaryl array (4 I).
Recombinant Baculoviruses, Infection of Sf-9 Insect Cells
and Cytosolic Lysates Preparation.
Infect of Sf-9 cells with Statl, Stat3, JakI, and c-Src
recombinant baculoviruses and preparation of the cell lysates
containing activated Statl or Stat3 have been previously
described (9, 2I).
Stat3 Inhibitory Property of S3I-M200I; Nuclear Extract
Preparation and Gel Shift Assays.
In the previously reported dissociation-reassociation
analysis (9, IO, 20), two independently-prepared cell lysate,
one containing only activated Stat3:Stat3 dimer and the other
containing only activated Statl :Statl dimer (2I ), were mixed
together and pre-treated with or without increasing concentration of S3I-M200I and subjected to STAT DNA-binding
assay with EMSA analysis.
Nuclear extract preparation from cells and EMSA were
carried out as previously described (9-I2, I 6, I 8, 40). Nuclear
extract preparations from v-Src-transformed (NIH3T3/vSrc) or EGF-stimulated NIH3T3/hEGFR fibroblasts, or
tumor cell lines were subjected to EMSA. The 32P-labeled
oligonucleotide probe used was hSIE (high affinity sis-induc-

ible element from the c-fos gene, m67 variant, as reported by
Wagner et al. (42), and that binds Statl and Stat3. Except
where indicated, inhibitor compound was pre-incubated with
the nuclear extract for 30 min at room temperature prior to
incubation with radiolabeled hSIE probe. Where necessary,
cells were stimulated with recombinant human EGF (rhEGF)
for 5-I 5 min prior to preparation of nuclear extracts. Bands
corresponding to DNA-binding activities were scamied and
quantified for each concentration of compound and plotted as
percent of control (vehicle) against concentration of compound, from which the IC50 values were derived, as previously reported (9, IO, 42).
Immunoprecipitation (i.p.) and SDS-PAGE/Western Blot
Analysis.
Whole-cell lysates prepared in boiling SDS sample-loading buffer. i.p. from lysates using monoclonal anti-Stat3 antibody (Cell Signaling Technology), and the probing of nitrocellulose membranes with primary antibodies and detection
of horseradish peroxidase-conjugated secondary antibodies
by enhanced chemiluminescence (Amersham Biosciences)
were done, as previously described (I3, I7, I9, 2I). The
probes used were anti-Stat3 (Santa Cruz), anti-pTyr705Stat3
(Cell Signaling Technology), anti-YFP antibodies (Santa
Cruz), anti-Bcl-xL, anti-pSrc, anti-Src, anti-pJakI, anti-JakI,
anti-pErI/2 and anti-ErkI/2, and b-actin (Cell Signaling
Technology).
Dissociation-Reassociation Analysis.
The dissociation-reassociation analysis with EMSA analysis was performed, as previously done (IO, 20).
Immunohistochemistry.
The indirect peroxidase-anti peroxidase test was performed
on cytospins prepared from cell lines (control and treated with
50 mM S3I-M200I for 48 h). Immunostaining was performed
for p Y705Stat3 with a rabbit anti-human polyclonal pYStat3
antibody (Cell Signaling Technology) and for Bcl-xL with
rabbit monoclonal (EIS) antibody (Abeam, Inc., Cambridge,
Mass.) with rabbit immunoglobulins as negative controls
using avidin-biotin-peroxidase complexes (Vector Laboratories, Burlingame, Calif.). After incubation and blocking of
endogenous peroxidase and nonspecific background staining
in 3% hydrogen peroxide and methanol for 20 min, slides
were washed with PBS, treated with I .5% normal serum and
3% BSA, and incubated with the pY705Stat3 or Bcl-xL primary antibodies overnight at 4° C. Slides were rinsed in PBS
and incubated with a biotinylated secondary antibody (Vector
Laboratories) for 60 min, followed by incubation with avidinbiotin-peroxidase complex for I hat room temperature. Chroma gen was developed with Nova-Red. All slides were counterstained with hematoxylin for 30 s before dehydration and
mounting. Phospho Y705Stat3 or Bcl-xL positive cells were
stained red (due to Nova-Red) and negative cells were stained
blue (due to hematoxylin).
Lck-SH2 Domain ELISA Assay.
An ELISA assay for the binding ofLck-SH2 domain with
its conjugate phosphopeptide, biotinyl-e-Ac-EPQpYEEIELOH, was carried out, as previously described (13, 22). Absorbancereading (450 nm) for the peroxidase reaction was determined with an ELISA plate reader.
Fluorescence Microscopy.
NIH3T3/vSrc cells were either stably transfected with
Stat3-YFP construct (23), or growing in 96-well plates on
chamber slides were transiently transfected with the Stat3YFP plasmid (23) using Lipofectamine 2000 for 24 h according to the manufacturer's protocol (Roche), treated with or
without S3I-M2001 for different times, and examined under
Nikon Eclipse TE200 fluorescence microscope (Nikon).
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Images were captured and processed by NIKON NIS element-Basic research software.
Confocal Microscopy.
NIH3T3/hEGFR cells were grown in multi-cell plates and
treated with or without S3I-M2001 for3 h prior to stimulation
by rhEGF (10 ng/ml) for 10 min or NIH3 T3/vSrc cells were
grown in multi-cell plates or chamber slides and cells were
fixed with 4% paraformaldehyde for 15 min. Cells were
washed 3 times in PBS, permeabilized with 0.2% Triton X for
5 min, and further washed 3-4 times with PBS. Specimens
were then blocked in 5% goat serum for 60 min and incubated
with Stat3 (Cell Signaling Technology) or Hook2 (Santa
Cruz, Santa Cruz, Calif.) antibody at 1:50 dilution at 4° C.
overnight. Subsequently, cells were rinsed 4-5 times in PBS,
incubated with Alexa fluor 488 rabbit antibody (Molecular
probe, Eugene, Oreg.) for (Stat3 detection) or NL637 goat
antibody (R&D Systems, Minneapolis, Minn.) for Hook2 for
1-2 hat room temperature in the dark. Specimens were then
washed 5 times with PBS, covered with cover slides with
VECTASHIELD mounting medium containing DAPI, and
examined immediately under Lei ca TCS SP5 confocal microscope (Germany) at appropriate wavelengths depending on
GFP or YFP. Images were captured and processed using the
Leica TCS SP 5 software.
Soft-Agar Colony Formation Assay.
Colony formation assays were carried out in six-well
dishes and colonies were enumerated as previously described
(19). Treatment with S3I-M2001 was initiated 1 day after
seeding cells in soft-agar suspension by adding 75-100 mL of
medium with or without compound, and repeated every three
days, until large colonies were evident.
Cell Viability Assay, TUNELAnalysis, andAnnexin V Binding and Flow Cytometry.
Normal NIH3T3 and NIH3T3/v-Src mouse fibroblasts
growing in culture were treated with or without 10-100 mM
S3I-M2001 for 48 h. Cells were then visualized under light
microscope and photographed with a digital camera.
Proliferating cells in 96-well plates were treated with
50-300 mM S3I-M2001for48 h for WST-1 assay, according
to manufacturer's (Roche) instructions, or cells growing in
culture and treated with or without S3I-M2001 for 48 h were
harvested for analysis by terminal nucleotidyl transferase
mediated dUTP nick end labeling (TUNEL) staining according to supplier's (Roche) instructions to detect apoptotic
cells. In some cases, cells were first transfected with the
plasmid forthe Stat3 SH2 (ST3-SH2) domain or mock-transfected (pcDNA3 empty vector) for 24 h or untransfected prior
to treatment with S3I-M2001 for an additional 24-48 h. Cells
were then detached and analyzed by Annexin V binding (BD
Biosciences, San Diego) according to the manufacturer's protocol and Flow Cytometry to quantify the percent apoptosis.
Cell Migration and Matrigel Invasion Assays.
Cell migration experiments were carried out using BioCoat migration chambers (Becton Dickinson, Franklin, N.J.)
of24-well companion plates with cell culture inserts containing 8 mm pore size filters, according to the manufacturer's
protocol. Briefly, tumor cells (5x104/500 ml) were added to
each insert (upper chamber) with or without S3I-M2001 and
medium with serum (10% FBS) as the chemoattractant was
placed in each well of a 24-well companion plate (lower
chamber). After 24-h incubation (37° C., 5% C02), the filters
were removed and the upper surface was wiped with a cottontipped applicator to remove non-migratory cells. Cells that
had migrated through the filter pores and attached to bottom
surface of the filter were fixed and stained. The membranes
were mounted on glass slides and cells from 10 random
microscopic fields (x400 magnification) were counted. Cell

invasion experiments were performed using same Bio-Coat
invasion chambers (Becton Dickenson), as already described,
except that here, filters (8 mm) were used coated with the
basement membrane matrigel. Percent inhibition is calculated as 100-y, where y equals residual number of stained
cells in the treated/total number in the control xlOO.
Mice and In Vivo Tumor Studies.
Six-week-old female athymic nude mice were purchased
from Harlan and maintained in the institutional animal facilities approved by the American Association for Accreditation
of Laboratory Animal Care. Athymic nude mice were injected
subcutaneously in the left flank area with 5x106 human breast
cancer MDA-MB-231 cells in 100 mL of PBS. After 5 to 10
days, tumors of a diameter of3 mm were established. Animals
were grouped so that the mean tumor sizes in all groups were
nearly identical, given S3I-M2001 i.v. at 5, 10 and 20 mg/kg
every 2 or every 3 days for 26 days and monitored every 2 or
3 days, and tumor sizes were measured with calipers. Tumor
volume was calculated according to the formula V=0.52xa2x
b, where a, smallest superficial diameter, b, largest superficial
diameter.
Results and Discussion
Computational Modeling of the Stat3 SH2 Domain-ISS 610
Complex.
Close structural analysis of the lowest genetic optimization
for ligand docking (GOLD) (15) conformation of ISS 610
(yellow) (IC50=42 µM for inhibition of Stat3:Stat3 (10))
bound within the Stat3 SH2 domain (FIG. IA), per the X-ray
crystal structure of Stat3b (14), indicated key structural
requirements for hydrophobic, hydrogen-bonding, and electrostatic interactions critical for tight binding. Appropriate
candidate binders are suitably-substituted heterocyclic systems that reproduce the critical ISS 610-Stat3 interactions.
Hence, S3I-M2001 (FIG. IB), which contained a central
oxazole core with two hydrophobic substituents to complement the relatively hydrophobic protein surface and a pTyr
group to bind to the phosphate recognition residues of the
third pocket, and which superimposes well with the parent
ISS 610 docked into the same SH2 cavity (FIG. IA). Docking
studies of S3I-M2001 identified significant complementary
interactions between the protein surface and the molecule.
The pTyr moiety is bound tightly within a hydrophilic cleft
composed of Arg609, Ser613 and Ser611. This important
contact may predetermine the subsequent orientations of the
two lipophilic groups within the hydrophobic regions of the
SH2 domain. The naphthy1appendage makes significant contact with the Ile634 side chain and the lipophilic hexyl substituent is partially encased within a hydrophobic channel
composed primarily of Phe716 and Trp623. Positive cooperativity may exist between these subunits to provide a highly
potent binding agent for the SH2 active site.
Stat3-Inhibitory Property of S3I-M2001.
Per DNA-binding assay/EMSA analysis (see "Methods"
for details). S3I-M2001 favorably disrupts Stat3 activity in
vitro in nuclear extracts containing activated Stat3 (FIG. 2A,
left panel) or in lysates from Sf-9 cells containing activated
Stat3, and preferentially inhibits Stat3 activity over Stat! by
2-fold (IC50 values (mM), Stat3:Stat3, 79±09; Statl:Stat3,
92±11; and Statl:Statl, 159±06 (FIG. 2A, middle and right
panels). Similarly, per DNA-binding assay/EMSA analysis
(FIG. 2B). SDS-PAGE/Westem blot (FIG. 2C) and immunocytostaining analyses, S3I-M2001 inhibited constitutive
Stat3 Tyr phosphorylation and activation in the NIH3T3/vSrc and the human breast cancer MDA-MB-231 and MDAMB-435 cell lines that harbor constitutively-active Stat3 (1618) (FIG. 2B, lanes 1-13, and 2C, lanes 1-6), and
preferentially inhibited the epidermal growth factor (rhEGF)-
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induced Stat3 activation over that of Statl in the mouse fibroblasts overexpressing the human EGF receptor (NIH3T3/
hEGFR) (FIG. 2B, right panel). Supershift analysis with antiStat3 antibody shows protein:DNA probe complex contains
Stat3 (FIG. 2B, left panel, lane 8). By contrast, the plaid,
pSrc and pErkl/2 (MAPKs) in NIH3T3/v-Src fibroblasts are
not repressed by S3I-M2001(FIG.2C, lanes 7-12), indicating
minimal effect on non-Stat3-related proteins. Furthermore,
transient transfection and luciferase reporter studies showed
S3I-M2001 inhibited v-Src-induced Stat3-dependent
pLucTKS3 luciferase reporter, but not the v-Src-induced
Stat3-independent pLucSRE luciferase reporter (17, 19), in a
similar manner to the effect of the transient co-expression of
the dominant-negative Stat3b (FIG. 3A) (17, 19).
To confirm the disruption of Stat3:Stat3 dimerization, the
previously reported dissociation-reassociation analysis (9,
10, 20) was performed using pooled cell lysates of independently-prepared lysates of activated Statl and Stat3 (details
are provided in Supplementary Material, "RESULTS"). Statl
or Stat3 DNA-binding activity was evident in their respective
cell lysates (FIG. 3B, lanes 1 and 2) and present together in
the pooled lysates (FIG. 3B, lane 3). Pooled lysate treated
with S3I-M2001 showed a concentration-dependent diminution ofStat3:Stat3 DNA-binding activity (FIG. 3B, lanes 3-6)
ahead of a diminishing Statl :Statl homodimer activity (FIG.
3B, lanes 5-7), and the appearance of an intermediate band
corresponding to Statl: Stat3 heterodimer activity, which was
hitherto not present (FIG. 3B, lanes 5 and 6). The formation of
the Statl :Stat3 band is due to the re-association between
transient monomers of active Stat3 and Statl (9, 10). The
disappearance of the activities for Stat3:Stat3 (FIG. 3B, lanes
5-7) and Statl:Stat3 (FIG. 3B, lane 7) is due to dimer disruption, as previously observed forISS 610 (9, 10), and suggests
a preferential disruption of Stat3:Stat3 over Statl:Statl
homodimer (FIG. 2A, middle and right panels). By contrast,
in vitro ELISA study of the pTyr-SH2 domain interaction
between the unrelated Lek SH2-GST and its cognate phosphopeptide, biotinyl-e-Ac-EPQpYEEIEL-OH (22) (FIG. 3C,
4th bar) showed minimal effect of S3I-M2001 at 30 or 100
mM (FIG. 3C, compare bars 5 and 6 to bar 4). Thus, S3IM2001 selectively disrupts Stat3: Stat3 dimers, thereby inhibiting Stat3 DNA-binding and transcriptional activities, while
not affecting the Lck-SH2 domain function. On whether disruption of Stat3 dimerization inhibits nuclear translocation,
immunofluorescence imaging/confocal microscopy for the
nuclear localization of Stat3 in EGF-stimulated NIH3T3/
hEGFR mouse fibroblasts revealed a strong EGF-induced
nuclear staining of Stat3 in the absence of S3I-M2001 (FIG.
3D, 3rd panel from left), which was significantly attenuated
upon treatment of cells with S3I-M2001 (FIG. 3D, 4th panel
from left), suggesting inhibition ofStat3 activation blocks its
nuclear localization.
Intracellular Stat3 Processing.
Malignant cell requirement for persistently-active Stat3 for
the maintenance of the malignant phenotype is well-established (17-19, 32, 33). How tumor cells regulate Stat3 to meet
this requirement, however, is not defined. Moreover, while
the inhibition of aberrant Stat3 activity results in malignant
cells demise (9-13), the molecular details of Stat3 cellular
processing and the fate of the protein within the context of
such an inhibition have not been explored. Given S3IM2001 's specific anti-Stat3 properties, it was used to probe
the intracellular processing and localization dynamics of
aberrant Stat3. Fluorescent microscopy (Nikon Eclipse
TE200) (FIG. 4A) and laser scanning confocal microscopy
(FIG. 4B-4E) of the NIH3T3/v-Src fibroblasts stably-transfected with the yellow fluorescent protein (YFP)-tagged Stat3

(Stat3-YFP) plasmid (23) (NIH3T3/v-Src/Stat3-YFP)
showed a stronger nuclear Stat3-YFP signal, consistent with
constitutive Stat3 activation (FIGS. 4A, 4B and 4D, right
panel, and 4E). Treatment with S3I-M2001 induced a timedependent decrease in the Stat3-YFP fluorescence; there is no
change in signal at 1 h-treatment or less, while an increasing
degree ofStat3 fluorescence loss becomes evident from 2-5 h,
100-300 mM S3I-M200 I -treatment (FIG. 4A, time t=O to t=6
h, left panels; arrows denote Stat3-YFP signal; FIG. 4B,
second column from left compared to first, time t=O to t=2 h:
FIG. 4D, right panel, time t=O to t=5 h)). Phase contrast
microscopy showed cellular integrity was maintained (FIG.
4A, time t=O to t=6 h, right panels; arrows identify cells
remaining or originally positive for fluorescent signal). Protein degradation can result in fluorescence signal loss (29).
Accordingly, the presence of MG132 proteasome inhibitor
prevented the fluorescence loss (FIG. 4B, third colunm from
left), while MG132 alone has no appreciable effect (FIG. 4B,
fourth colunm from left), suggesting the Stat3 fluorescence
decay may involve the ubiquitin-proteasome degradation
pathway. In contrast, similar studies with the v-Src transformed fibroblasts stably expressing the non-Stat3 related
Green Fluorescent Protein (GFP) (NIH3T3v-Src/GFP)
showed no evidence ofGFP signal change by S3I-M2001 or
the proteasome inhibitor MG132 (FIG. 4C and FIG. 4D, left
panel), thus excluding the possibility of non-specific fluorescence quenching or photo bleaching. Moreover, immunoblotting of whole-cell lysates from NIH3T3/v-Src/Stat3-YFP
fibroblasts showed reduced Stat3-YFP expression in S3IM2001-treated cells in 3 and 5 h, which was similarly partially restored when cells were co-treated with MG 132 (FIG.
SA, lanes 3 and 4 vs. lanes 5 and 6). That only a partial
corresponding decrease in total Stat3 protein occurred (FIG.
SA, middle panel, lanes 3 and 4) suggests a weak proteasome
activity against total Stat3 protein. However, immunoblotting
for ubiquitin of Stat3 immunoprecipitates (i.p.) from
NIH3T3/v-Src fibroblasts showed a strong and time-dependent increase in the level ofStat3 ubiquitination following the
S3I-M2001 treatment, which occurred in parallel with partial
and strong Stat3 protein reductions at 5 and 24 h, respectively
(FIG. SB). These findings together raise the possibility there
is an impairment of proteasome function (24, 25) at the early
hours (<5 h) of S3 I-M2001-treatment and suggests additional
mechanisms contribute to the Stat3 fluorescence signal decay.
Protein misfolding can lead to ubiquitin-proteasome degradation, and aggregation into aggresomes (26-29). Aggresomes can lead to fluorescence signal loss (29) and impairment of proteasome function (24, 25). Using laser scanning
confocal microscopy, we observed that the specific loss of
Stat3-YFP signal in the NIH3T3/v-Src/Stat3-YFP that follows S3I-M2001-treatment (FIG. 4D, right colunm and 4E
right column, time t=O to t=5 h) is accompanied by aggregated bodies, possibly aggresomes of Stat3-YFP, within 5 h
of S3I-M2001 treatment (FIG. 4E, right bottom panel; red
arrow denotes bodies). By contrast, Cisplatin treatment produced no such effect (FIG. 4E middle column). Confirming
these data, immunofluorescence imaging/confocal microscopy of Stat3 in NIH3T3/v-Src fibroblasts revealed that in
contrast to the strong nuclear fluorescence of activated Stat3
protein that occurred in "dot-like" structures resembling
nuclear bodies (23) and the low cytoplasmic signal in the
untreated cells (FIG. 6A, control), a strongly reduced Stat3
fluorescence signal occurred that coincided with the appearance of perinuclear aggregated bodies, possibly aggresomes
in the S3I-M2001-treated cells within 3 hand later, with a
stronger aggresome formation at 24-h treatment (FIG. 6A.
S3I-M2001, time t=0.5 to t=24 h). Thus. S3I-M2001 pro-
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motes the disruption of activated Stat3 from "dot-like"
nuclear bodies (23) into perinuclear aggresomes, which may
explain the apparent low proteasome-mediated degradation
in the early period of S3I-M2001-treatment. The Stat3 aggresome formation and signal loss are events specific to S3IM2001, because they are not induced by Cisplatin (FIG. 6A,
Cisplatin) and occur in the early hours (<5 h) of treatment
prior to change in cellular integrity (FIG. 4A and data not
shown). The resting of NIH3T3/v-Src fibroblasts for 2 h
following a 5-h S3I-M2001-treatment led to a partial recovery of Stat3 signal, while aggresomes remained (FIG. 6B,
upper panel, compare right column vs. middle column, 5
h-treated cells without recovery vs. control), suggesting
effect of S3I-M2001 still persisted in the 2 h following drug
removal. By contrast, Stat3 immunofluorescence was completely recovered within 19-h of resting after 5-h treatment
(FIG. 6B, lower panel, compare right column vs. middle
column, 5 h-treated cells without recovery vs. control), either
because S3I-M2001 's effect on Stat3 was reversible or that
new Stat3 protein was synthesized. To investigate further and
to demonstrate the perinuclear aggresome localization,
immunofluorescence imaging/confocal microscopy was performed on NIH3T3/v-Src fibroblasts harboring constitutively-active Stat3 to assess the co localization with Hook2, an
adaptor protein important for the association of cargos with
dynein for the transport on microtubules and for aggresome
formation (26). As expected, a strong nuclear Stat3 staining is
observed (FIG. 6C, left upper panel), which contrasts a
Hook2 expression that appears ubiquitous (FIG. 6C, middle
upper panel), without any evidence of colocalization. By
contrast, S3I-M2001 induced the formation of perinuclear
aggregated bodies of Stat3 (FIG. 6C, left bottom panel),
which colocalized with Hook2 (FIG. 6C, middle and right
bottom panels; red arrows denote aggregated bodies), suggesting a possible association between the two proteins and
implicating the Hook proteins in the Stat3 aggresome formation.
Together, our studies herein disclosed are the first on the
localization dynamics and the molecular mechanisms for terminating Stat3 function in response to a small-molecule
inhibitor. Two possible mechanisms may account for the loss
of aberrant Stat3 function: one involves protein ubiquitination and an early aggregation into perinuclear aggresomes
(28), and a late-phase proteasome-mediated degradation
event, potentially a "quality control" mechanism for Stat3
(34), given its apparent unnatural state promoted by S3IM2001. The effects of early aggresome formation may be
reversible, while the late-phase events are irreversible and
lead to a long-term loss of Stat3 function, with biological
consequences. The perinuclear aggresome formation also
suggests a nuclear-to-perinuclear exit of disrupted "activated" Stat3 by as yet undetermined mechanisms.
Suppression of Malignant Phenotype and Tumor Growth.
Consistent with Stat3's importance in maintaining the
malignant phenotype (17), WST-1 assay (FIG. 7A) and trypan blue exclusion/cell counting revealed S3I-M2001-induced growth inhibition and a greater than 2-fold selective
loss of viability of the human breast (MDA-MB-435 and
MDA-MB-231) and Pancreatic (Pane-I) cancer cells, and the
NIH3T3/v-Src fibroblasts, which all harbor constitutivelyactive Stat3, with EC50 values in the range of 50-100 mM,
compared to effects on normal NIH3T3 fibroblasts, and the
human breast (MDA-MB-453) and Pancreatic (MiaPaca-1)
cancer cells that lack aberrant Stat3 (EC50 values of 120-300
mM) (FIG. 7A). Furthermore, S3I-M200 I blocked growth in
soft-agar of the NIH3T3/v-Src and the pancreatic cancer,
Pane-I cells (FIG. 7B), and induced morphology changes in
NIH3T3/v-Src, in contrast to no appreciable effects on v-Ras

transformed fibroblasts (NIH3T3/v-Ras) lacking constitutively-active Stat3 (FIG. 7B). Terminal nucleotidyl transferase-mediated nick end labeling (TUNEL) (FIG. 7C) and
Annexin Vbindingwith Flow CytometricAnalyses (FIG. 7D,
first and third pairs of bars) showed strong apoptosis in the
NIH3T3/v-Src (3T3/v-Src) and MDA-MB-231 and MDAMB-435 cells harboring aberrant Stat3 and treated with S3IM2001, compared to minimal effect on normal NIH3T3,
human breast epithelial MCF-1 OA, breast cancer MDA-MB453, and HUVEC, HAEC, and HL-60 cells that do not contain aberrant Stat3. Validating that the S3I-M2001-induced
apoptosis is due to interaction with its molecular target (Stat3
SH2 domain), NIH3T3/v-Src fibroblasts (3T3/v-Src) transiently-transfected with a plasmid encoding the Stat3 SH2
domain (3T3/v-Src/ST3-SH2) and treated with S3I-M2001
showed diminished apoptosis (FIG. 7D, compare middle two
bars) compared to mock-transfected (3T3/v-Src/pcDNA3)
(FIG. 7D, left two bars) or untransfected cells (FIG. 7D, right
two bars). Moreover, Western blot analysis showed diminished Bcl-xL expression, a known Stat3-regulated and antiapoptotic gene (30 ), in the S3 I-M200 I -treated NIH3 T3/v-Src
and MDA-MB-43 5 cells (FIG. 7E), suggesting repressed BclxL expression is part of the underlying mechanism for the
S3I-M2001-induced apoptosis.
Given Stat3 's importance in tumor growth and tumor progression (31 ), matrigel assay using Bio-Coat migration
chambers showed significant S3I-M2001-induced inhibition
of the migration of NIH3T3/v-Src (76%). MDA-MB-231
(37%) and Pane-I (21 %), and the invasion ofNIH3T3/v-Src
(28%), MDA-MB-231 (48%)andPanc-I (38%)cellsharboring constitutively-active (FIG. SA: percent inhibition in
parenthesis defined in "Methods" section). Furthermore, in
xenograft models of human breast (MDA-MB-231 cells that
harbors aberrant Stat3) tumor-bearing mice, the i.v. injection
of S3I-M2001 at 5, 10, and 20 mg kg-I, but not vehicle
(control) every 2 or 3 days for 26 days, strongly inhibited
growth of tumors (FIG. SB). Animals remained viable at the
highest (20 mg kg-I) dose applied. DNA-binding assay with
EMSA analysis and SDS/AGE-Westem blotting of lysates
from residual tumor tissues extracted from representative
control and treated mice showed abrogated Stat3 activity and
pTyr levels in S3I-M2001-treated tumors (Tl and T2) (FIGS.
SC and SD). These findings together demonstrate S3 I-M2001
induces anti tumor cell effects and tumor regression in part by
targeting the Stat3 SH2 domain and inhibiting Stat3-mediated tumor processes (3, 6, 7, 17, 32, 38, 39). Moreover,
S3I-M2001 compares favorably with other Stat3 SH2
domain-targeting small-molecule inhibitors, including S3I201, which was obtained by computational modeling and
virtual chemical library-screening (13), and represents a significant improvement over its peptidomimetic predecessors
(10).
The present disclosure provides the first study of the cellular processing and stability of aberrant Stat3 in malignant
cells within the context ofinhibition by a chemical probe that
has implications for the many human tumor cells, including
the human breast and pancreatic cancer cells that harbor
aberrant Stat3. The general applicability of the current study
to other previously-identified Stat3 inhibitors, including the
g-quartet oligonucleotides (35), peptide aptamers (36), platinum (IV) complexes (11, 12), and STA-21 (NSC 628869)
(37), however, is unclear, as those other agents have different
modes ofinhibitionofStat3 from S3I-M2001.Altogether, our
studies establish the proof-of-concept for the antitumor
effects of S3I-M2001 that correlates with disruption of constitutively-active Stat3:Stat3 dimers, while using S3I-M2001
as a chemical probe to investigate the molecule dynamics of
termination of Stat3 function following inhibition. Accordingly, the novel compound S3I-M2001 herein disclosed may
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also be referred to as an anti-cancer agent, a cytotoxic agent
and/or a chemotherapeutic agent.
Accordingly, in the drawings and specification there have
been disclosed typical preferred embodiments of the invention and although specific terms may have been employed, the
terms are used in a descriptive sense only and not for purposes
of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of
the invention as described in the foregoing specification and
as defined in the appended claims.
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That which is claimed:
1. A compound, or a pharmaceutically acceptable salt
thereof, having a structure represented by a formula:
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13. A method of treating a mammalian cancer having a
dysfunctional Stat3 protein, the method comprising contacting the cancer with the compound having a structure represented by a formula:
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16. A method of inhibiting a mammalian cancer having a
constitutively active Stat3, the method comprising contacting
the cancer with an effective amount of the compound of claim
1.
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14. A method of treating a human breast or pancreatic
cancer cell, the method comprising contacting at least one cell
of a human breast or pancreatic cancer with the composition
of claim 2.
15. A method of treating a mammalian cancer having a
dysfunctional Stat3 protein, the method comprising contacting the cell with the composition of claim 2.

20

17. A method of treating a human breast cancer or pancreatic cancer, the method comprising contacting the cancer with
an amount of the compound of claim 1 effective to inhibit
Stat3 activity therein.
18. A method of treating human breast or pancreatic cancer
having a constitutively active level ofStat3, the method comprising administering a sufficient amount of the compound of
claim 1 to contact said cancer.
19. A method of patient treatment effective for inhibiting
growth of a human breast cancer tumor, the method comprising administering to the patient a sufficient amount of the
compound of claim 1 to contact the cancer tumor.
20. A method of inhibiting migration of malignant cells
from a mammalian cancer, the method comprising contacting
the cells with the compound of claim 1.
21. A method of inhibiting growth of a human breast or
pancreatic cancer tumor, the method comprising contacting at
least one cell of a human breast or pancreatic cancer tumor
with the compound of claim 1.
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